Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human endostatin + gemcitabine + cisplatin
- Development stage
- Unknown
- Lead developer
- Simcere Pharmaceutical Group
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapy consisting of recombinant human endostatin (Endostar), gemcitabine, and cisplatin. This regimen combines an anti-angiogenic agent with traditional chemotherapy drugs. Recombinant human endostatin is a 20 kDa protein derived from type XVIII collagen that inhibits angiogenesis by targeting endothelial cells, while gemcitabine and cisplatin are cytotoxic agents that directly target cancer cells. The combination leverages the ability of endostatin to normalize tumor vasculature, potentially enhancing the delivery and efficacy of the chemotherapy drugs.
- Brand names
- Endostar
- Other names
- Endostar + GPEndostar plus GPrecombinant human endostatin + gemcitabine + cisplatin
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)MMP9 (Matrix metalloproteinase-9)MMP2 (Matrix metalloproteinase-2)DNADNA polymerase familyMMP13 (Matrix metalloproteinase-13)
Beyond the preview
Go deeper on recombinant human endostatin + gemcitabine + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human endostatin + gemcitabine + cisplatin.